论文部分内容阅读
目的对以人白介素－２在原代培养骨骼肌细胞中的表达作为肿瘤基因治疗模式进行新的探索；方法将人白介素－２ｃＤＮＡ片段与ＣＭＶ启动子及ＲＳＶ启动子重组，通过Ｌｉｐｏｆｅｃｔｉｎ介导将得到真核表达载体ｐＣＭＶ－ＩＬ２和ｐＲＳＶ－ＩＬ２转入原代培养的骨骼肌细胞，并用免疫组织化学方法观察白介素－２的表达；结果ｐＣＭＶ－ＩＬ２和ｐＲＳＶ－ＩＬ２经酶切鉴定正确，免疫组织化学观察到约有１０％左右细胞表达了白介素－２ｃＤＮＡ；结论不同启动子表达情况并无差别，质粒ＤＮＡ为今后肿瘤基因治疗提供了新的途径
Objective To explore the expression of human interleukin-2 (IL-2) in primary cultured skeletal muscle cells as a model of oncogene therapy. Methods Human interleukin-2 cDNA was recombined with CMV promoter and RSV promoter and mediated by Lipofectin The expression vectors pCMV-IL2 and pRSV-IL2 were transfected into primary cultured skeletal muscle cells and the expression of interleukin-2 was detected by immunohistochemistry. Results The pCMV-IL2 and pRSV-IL2 were identified by restriction enzyme digestion and immunohistochemistry To about 10% of the cells expressed interleukin-2 cDNA; Conclusion There is no difference in the expression of different promoters, plasmid DNA for future cancer gene therapy provides a new way